2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: ASN.2008060628v1 20/3/604    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Mitch, W. E. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Mitch, W. E.

IL-6 and Serum Amyloid A Synergy Mediates Angiotensin II–Induced Muscle Wasting

Liping Zhang^*, Jie Du^*, Zhaoyong Hu^*, Guofeng Han^*, Patrice Delafontaine, Gabriela Garcia^* and William E. Mitch^*

^* Nephrology Division, Baylor College of Medicine, Houston, Texas; and Cardiology Division, Tulane University School of Medicine, New Orleans, Louisiana

Correspondence: Dr. Jie Du, Nephrology Division, M/S: BCM 285, Baylor College of Medicine, Alkek N-520, One Baylor Plaza, Houston, TX 77030. Phone: 713-798-3023; Fax: 713-798-5010; E-mail: jdu{at}bcm.edu

Received for publication June 22, 2008. Accepted for publication October 29, 2008.

Animal studies suggest that increased levels of circulating angiotensin II (AngII) could contribute to the loss of lean body mass in chronic kidney disease, but the mechanism by which this occurs is unclear. Here, AngII infusion increased circulating IL-6 and its hepatic production in wild-type mice, suggesting that AngII-induced inflammation may trigger muscle loss. AngII infusion also stimulated the suppressor of cytokine signaling (SOCS3) in muscle, which led to loss of insulin receptor substrate 1 (IRS-1), thereby impairing insulin/IGF-1 signaling and enhancing protein degradation. All of these responses to AngII were suppressed in IL-6–deficient mice. Recombinant human IL-6 (rhIL-6) treatment of cultured myotubes only minimally increased SOCS3, however, suggesting the contribution of other mediators. Because AngII increases hepatic serum amyloid A (SAA) expression in an IL-6–dependent manner, we treated wild-type mice with rhIL-6 and an SAA1-overexpressing adenovirus; the combination led to a significantly greater increase in SOCS3 and decrease in IRS-1 compared with either rhIL-6 or SAA1 alone. We observed similar effects on SOCS3 and IRS-1 when we treated cultured muscle myotubes with rhIL-6 and SAA1. Taken together, these results suggest an interorgan response to high levels of AngII: Hepatic production of IL-6 and SAA increases, and these mediators act synergistically to impair insulin/IGF-1 signaling, which promotes muscle proteolysis. Targeting the high levels of IL-6 and SAA in catabolic disorders might be a therapeutic approach to prevent muscle wasting.

This article has been cited by other articles:

				L. Zhang, L. Ran, G. E. Garcia, X. H. Wang, S. Han, J. Du, and W. E. Mitch Chemokine CXCL16 Regulates Neutrophil and Macrophage Infiltration into Injured Muscle, Promoting Muscle Regeneration Am. J. Pathol., December 1, 2009; 175(6): 2518 - 2527. [Abstract] [Full Text] [PDF]

				J. J. Carrero and P. Stenvinkel Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal Clin. J. Am. Soc. Nephrol., December 1, 2009; 4(Supplement_1): S49 - S55. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673